Table 2.
Relative risk ratios for treatment type, treatment paradigm and cancer stage between paTable 2019. versus 2020.
| Variable | RRR a | 95% Confidence Interval |
|---|---|---|
| SACT type | ||
| Chemotherapy | (Base outcome) | |
| Immunotherapy | ||
| 2019 | 1.00 | Ref. |
| 2020 | 1.69 | (1.35–2.11) |
| Biological/Targeted | ||
| 2019 | 1.00 | Ref. |
| 2020 | 1.27 | (1.11–1.45) |
| Combination Biological/Targeted | ||
| 2019 | 1.00 | Ref. |
| 2020 | 2.30 | (1.82–2.92) |
| Combined chemotherapy | ||
| 2019 | 1.00 | Ref. |
| 2020 | 0.99 | (0.77–1.24) |
| Combined immunotherapy | ||
| 2019 | 1.00 | Ref. |
| 2020 | 1.30 | (0.76–2.23) |
| Treatment Paradigm | ||
| Curative | (Base outcome) | |
| Neoadjuvant | ||
| 2019 | 1.00 | Ref. |
| 2020 | 0.34 | (0.21–0.57) |
| Adjuvant | ||
| 2019 | 1.00 | Ref. |
| 2020 | 0.36 | (0.22–0.59) |
| Radical | ||
| 2019 | 1.00 | Ref. |
| 2020 | 0.05 | (0.03–0.11) |
| Palliative | ||
| 2019 | 1.00 | Ref. |
| 2020 | 0.39 | (0.24–0.62) |
| Cancer stage | ||
| Stage I | (Base outcome) | |
| Stage II | ||
| 2019 | 1.00 | Ref. |
| 2020 | 1.44 | (1.01–2.05) |
| Stage III | ||
| 2019 | 1.00 | Ref. |
| 2020 | 1.11 | (0.80–1.54) |
| Stage IV | ||
| 2019 | 1.00 | Ref. |
| 2020 | 1.89 | (1.40–2.57) |
RRR a—Adjusted for age, sex, ethnicity and socioeconomic status.